Latest News

MMS Partners with I-ACT to Advance Children’s Clinical Trials

CANTON, Mich. (February 21, 2023) – MMS, a data-focused contract research organization (CRO) – announced its partnership with the Institute for Advanced Clinical Trials (I-ACT) to accelerate the development of life-saving therapeutics including vaccines, medicines, and medical devices for children.

MMS is a sponsor of I-ACT’s Spin Challenge, a creative way to raise funds to advance and accelerate children’s clinical trials. The event officially launches in early March when scores of pediatricians, pediatric nurses, pediatric social workers, and others who care deeply about children will visit Disney World and set a world record by riding Disney’s Spinning Tea Cups for three days.

In addition to its corporate sponsorship, MMS colleagues participated in the challenge by “spinning” in their own way, some on bicycles, with hockey pucks, bowling balls, and more.

“We are happy to partner with an organization like I-ACT whose values closely align with ours,” said Uma Sharma, Ph.D., Chief Executive Officer, MMS. “Our mission at MMS is to assist our clients in bringing life-changing therapies to patients worldwide, including expanding access to pediatric populations. At MMS, we support a variety of pediatric initiatives and approvals for our sponsors and understand the challenges of clinical work in this population.”

There is a gap in pediatric drug development because pediatric trials face many hurdles that adult trials do not, and recruitment is challenging. Hence, pediatric trials often take longer and fail more frequently. Nevertheless, this population needs new medicines with the same urgency as adults, as shown by the recent COVID vaccine development.

“We act because every child with a medical need deserves the best chance possible. That chance depends on a commitment to innovation, quality, and urgency in advancing medical therapies specifically for children,” said Betsy Garofalo, MD, Chair of the I-ACT Board of Directors. “I’m thankful we could connect I-ACT with an innovative company like MMS to help close the pediatric drug development gap.”

Learn more about participating in the Spin for Kids event or donate here.

About MMS

MMS Holdings (MMS) is an innovative, data-focused CRO that supports the pharmaceutical and biotech industries with a proven, scientific approach to complex trial data and regulatory submission challenges. Strong industry experience, technology-enabled services, and a data-driven approach to drug development make MMS a valuable CRO partner, creating compelling submissions that meet rigorous regulatory standards. With a global footprint across four continents, MMS maintains a 97 percent customer satisfaction rating.

Media Contact
Prasad Babu
media@mmsholdings.com

About I-ACT for Children

I-ACT for Children is a not-for-profit entity whose mission is to serve the pediatric community as an independent and connected organization to accelerate the clinical development of innovative therapeutic solutions to improve health outcomes in children. To learn more about I-ACT for Children, visit https://www.iactc.org.

Media Contact
Erika Lopez
Pace Public Relations
erika@pacepublicrelations.com
860-309-5887

Suggested For You

news

May 28th, 2025

MMS Named Finalist for Fierce CRO Award in Excellence in Client Service and Partnership, CEO shortlisted for the CRO Champion Award 

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

news

December 13th, 2023

MMS Supported Lykos Therapeutics: NDA Submitted to FDA for First Psychedelic-Assisted Therapy for PTSD

news

June 27th, 2022

Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration Between MAPS PBC and MMS Holdings

news

June 11th, 2020

Helping to Accelerate the Search for Solutions to the COVID-19 Crisis

news

June 9th, 2020

IGY Life Sciences Partners with MMS Holdings to Develop Novel COVID-19 Antibody Treatment

news

May 5th, 2020

Green Valley Pharmaceutical And MMS Holdings Collaborate to Gain FDA Approval To Begin Clinical Trial For The First Alzheimer's Drug In 17 Years

news

March 20th, 2020

MMS Announces One Million Dollar Award For Pharmaceutical Companies Developing A Vaccine For COVID-19

news

March 12th, 2020

Committed to the health of your projects during COVID-19

news

March 14th, 2016

MMS Funds $1 Million Zika Vaccine Development Award

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

August 9th, 2024

FDA Updates 2024 Language Access Plan